BeOne Medicines (ONC) 44th Annual J.P. Morgan Healthcare Conference summary

Key achievements and financial performance

• Achieved significant product revenue growth in 2025, with $3.8B in revenue, up 43% year-over-year, GAAP profitability, and strong cash flow, including $562M in free cash flow and a balance sheet exceeding $4B in cash.

• Reported diluted earnings per ADS of $1.96 and maintained a strong financial profile, enabling ongoing investment in pipeline and global expansion.

• Maintains a dual mandate of growth and margin expansion, investing in commercial assets and innovative pipeline for long-term value.

Clinical innovation and pipeline highlights

• BRUKINSA became the leading BTK inhibitor globally, setting new standards for efficacy and safety in CLL, with a 51% increase in quarterly revenue and PFS superiority to ibrutinib.

• Sonro (Sonrotoclax), a foundational BCL-2 inhibitor, received FDA breakthrough designation, priority review, and first approvals in relapsed/refractory CLL and MCL, with four submissions in 2025.

• Initiated five phase 3 trials in hematology and advanced multiple solid tumor assets, with six achieving proof of concept and five new molecules entering the clinic.

• BTK CDAC, a first-in-class degrader, showed 86% ORR and 79% 12-month PFS in phase 1 for relapsed CLL, with a phase 3 head-to-head trial against Pirto underway.

• R&D organization scaled to 4,800+ people, delivering 15 new molecular entities to the clinic in 18 months and targeting 8–10 NMEs annually.

Strategic advantages and operational execution

• Built an integrated global development and manufacturing organization of nearly 6,000, enabling rapid patient enrollment and fast proof of concept.

• Enrolled ~700 CLL patients in a global study across 20+ countries in 14 months, demonstrating rapid trial execution.

• Completed 200 dose escalation cohorts in two years, with a median of 1.5 months per cohort.

• Internal model, the Global Development Superhighway, provides speed, cost, and quality advantages over traditional CRO-based models.

• Capital allocation focuses on profitable growth, pipeline investment, and value-creating business development leveraging internal capabilities.